Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 3, 2005, Pages 1052-1058

  Dickey, D Thomas ^a   Wu, Y Jeffrey ^a   Muldoon, Leslie L ^a   Neuwelt, Edward A ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c L603 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CISPLATIN; CREATININE; SODIUM THIOSULFATE; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; EVOKED BRAIN STEM AUDITORY RESPONSE; FEMALE; HEARING DISORDER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; PROTECTION; RAT; TOXICITY; TUMOR CELL; UREA NITROGEN BLOOD LEVEL;

ACETYLCYSTEINE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL SURVIVAL; CISPLATIN; FEMALE; HEARING; KIDNEY; RATS; RATS, LONG-EVANS; SIGNAL TRANSDUCTION; THIOSULFATES;

EID: 23944447422     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.087601     Document Type: Article

References (32)

1. Ammer U, Natochin Y, David C, Rumrich G, and Ullrich KJ (1993) Cisplatin nephrotoxicity: site of functional disturbance and correlation to loss of body weight. Ren Physiol Biochem 16:131-145.
2. Arany I and Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460-464.
3. Basnakian AG, Kaushal GP, and Shah SV (2002) Apoptotic pathways of oxidative damage to renal tubular epithelial cells. Antioxid Redox Signal 4:915-924.
4. Bess FH, Dodd-Murphy J, and Parker RA (1998) Children with minimal sensorineural hearing loss: prevalence, educational performance and functional status. Ear Hear 19:339-354.
5. Blakley BW, Cohen JI, Doolittle ND, Muldoon LL, Campbell KC, Dickey DT, and Neuwelt EA (2002) Strategies for prevention of toxicity caused by platinum-based chemotherapy: review and summary of the annual meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001. Laryngoscope 112:1997-2001.
6. Blumenreich MS, Woodcock TM, Jones M, Richman SP, Gentile PS, Kubota TT, and Allegra JC (1985) High-dose cisplatin in patients with advanced malignancies. Cancer 55:1118-1122.
7. Campbell KCM, Rybak LP, Meech RP, and Hughes L (1996) D-Methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res 102:90-98.
8. Church M, Kaltenbach J, Blakley BW, and Burgio DL (1995) The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear Res 86:195-203.
9. Dickey DT, Muldoon LL, Kraemer DF, and Neuwelt EA (2004) Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hear Res 193:25-30.
10. Doolittle ND, Muldoon LL, Brummett RE, Tyson RM, Lacy C, Bubalo JS, Kraemer DF, Heinrich MC, Henry JA, and Neuwelt EA (2001) Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 7:493-500.
11. Feghali J, Liu W, and Van De Water TR (2001) L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope 111:1147-1155.
12. Fuertes MA and Castilla J (2003) Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 10:257-266.
13. Gilmer-Knight K, Kraemer DF, and Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: incidence and implications. J Clin Onc, in press.
14. Jones MM and Bassinger M (1989) Thiol and thioester suppression of cis-platinuminduced renal toxicity in rats bearing the Walker 256 carcinosarcoma. Anticancer Res 9:1937-1942.
15. Ludwig T and Oberleithner H (2004) Platinum toxicity in cultured renal cells. Cell Physiol Biochem 14:431-440.
16. Masuda H, Tanaka T, and Takahama U (1994) Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun 203:1175-1180.
17. Muldoon LL, Pagel MA, Kroll RA, Brummett RE, Doolittle ND, Zuhowski EG, Egorin MJ, and Neuwelt EA (2000) Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res 6:309-315.
18. Neuwelt EA, Brummett RE, Doolittle ND, Muldoon LL, Kroll RA, Pagel MA, Dojan R, Church V, Remsen LG, and Bubalo JS (1998) First evidence of otoprotection against carboplatin-induced hearing loss with a two compartment model in patients with CNS malignancy. J Pharmacol Exp Ther 286:77-84.
19. Neuwelt EA, Brummett RE, Remsen LG, Kroll RA, Pagel MA, McCormick CI, Guitjens S, and Muldoon LL (1996) In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res 56:706-709.
20. Neuwelt EA, Pagel MA, Hasler BP, Deloughery TG, and Muldoon LL (2001) Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res 61:7868-7874.
21. Neuwelt EA, Pagel MA, Kraemer DF, Peterson DR, and Muldoon LL (2004) Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther 309:594-599.
22. Razzaque MS, Ahsan N, and Taguchi T (2002) Role of apoptosis in fibrogenesis. Nephron 90:365-372.
23. Robbins KT, Kumar P, Wong FS, Hartsell WF, Flick P, Palmer R, Weir AB 3rd, Neill HB, Murry T, Ferguson R, et al. (2000) Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck 22:687-693.
24. Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, and Green GR (2000) P53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem 275:7337-7342.
25. Schweitzer VG (1993) Ototoxicity of chemotherapeutic agents. Otolaryngol Clin North Am 26:759-785.
26. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279.
27. Wu YJ, Muldoon LL, and Neuwelt EA (2005) The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 312:424-431.
28. Yildirim Z, Sogut S, Odaci E, Iraz M, Ozyurt H, Kotuk M, and Akyol O (2003) Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol Res 47:149-156.
29. Zafarullah M, Li WQ, Sylvester J, and Ahmad M (2003) Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60:6-20.
30. Zhan Y, van de Water B, Wang Y, and Stevens JL (1999) The roles of caspase-3 and bcl-2 in chemically-induced apoptosis but not necrosis of renal epithelial cells. Oncogene 18:6502-6512.
31. Zhang JG, Viale M, Esposito M, and Lindup WE (1999) Tiopronin protects against the nephrotoxicity of cisplatin in the rat. Hum Exp Toxicol 18:713-717.
32. Zunino F, Pratesi G, Micheloni A, Cavaletti E, Sala F, and Tofanetti O (1989) Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact 70:9-101.